EVFM (Evofem Biosciences) Other Current Receivables: $0.19 Mil (As of Mar. 2026)


What is Evofem Biosciences Other Current Receivables?

Evofem Biosciences EVFM -9.09% Other Current Receivables is $0.19 Mil as of Mar. 2026. The stock has 5 warning signs investors should review.

Evofem Biosciences's Other Current Receivables for the quarter that ended in Mar. 2026 was $0.19 Mil.

Evofem Biosciences's quarterly Other Current Receivables increased from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($0.38 Mil) but then stayed the same from Dec. 2025 ($0.38 Mil) to Mar. 2026 ($0.19 Mil).

Evofem Biosciences's annual Other Current Receivables stayed the same from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($0.00 Mil) but then increased from Dec. 2024 ($0.00 Mil) to Dec. 2025 ($0.38 Mil).

Evofem Biosciences Other Current Receivables Related Terms

Evofem Biosciences Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Evofem Biosciences's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evofem Biosciences Other Current Receivables Chart

Evofem Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.38

Evofem Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.38 0.19

Evofem Biosciences Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of $0.19 Mil mean?
Evofem Biosciences (EVFM) has a Other Current Receivables of $0.19 Mil as of Mar. 2026. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Evofem Biosciences and its competitors.
Is Evofem Biosciences' Other Current Receivables too high?
Evofem Biosciences' current Other Current Receivables is $0.19 Mil.
How does Evofem Biosciences' Other Current Receivables compare to LYRA and CLSDQ?
Evofem Biosciences' Other Current Receivables of $0.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Biotechnology company?
A good Other Current Receivables depends on the Biotechnology industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Evofem Biosciences and its competitors. Evofem Biosciences's current Other Current Receivables is $0.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evofem Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Evofem Biosciences (EVFM) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading 15% below its estimated fair value. The current Other Current Receivables is $0.19 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Evofem Biosciences (EVFM), the current Other Current Receivables is $0.19 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evofem Biosciences Business Description

Address 7770 Regents Road, Suite 113-618, San Diego, CA, USA, 92122
Evofem Biosciences Inc is a commercial-stage biopharmaceutical company committed to developing and commercializing products to address unmet needs in women's sexual and reproductive health. The company's product, Phexxi (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.